Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)
NCT03196115 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-02-13
Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Hyaline fibromatosis syndrome from the blood
Conditions
- Hyalinosis
- Hyaline Membrane Disease
- Juvenile Hyaline Fibromatosis
- Fibromatosis Hyalinica Multiplex Juvenilis
- Skin and Connective Tissue Diseases
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Peter Bauer, Prof. · Centogene GmbH
Eligibility
- Min Age
- 2 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-20
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- Germany
- India
- Sri Lanka
Study Locations
More Related Trials
-
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
NCT02654340 ·Status: TERMINATED
-
Biomarkers in Systemic Histiocytosis
NCT07157683 ·Status: NOT_YET_RECRUITING
-
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
NCT02370693 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Skin Tumors in Tuberous Sclerosis
NCT00001975 ·Status: RECRUITING
-
Microvascular and Fibrosis Imaging Study
NCT01758250 ·Status: COMPLETED
-
Oral Manifestations of Systemic Sclerosis
NCT02371005 ·Status: TERMINATED ·Phase: NA
-
Defining the Basis of Fibromuscular Dysplasia (FMD)
NCT01967511 ·Status: RECRUITING
-
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
NCT07015060 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
NCT07102394 ·Status: RECRUITING ·Phase: PHASE1
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Variability in Marfan Syndrome
NCT01707563 ·Status: COMPLETED ·Phase: NA
-
Optical Elastography of Systemic Sclerosis Skin
NCT02835196 ·Status: COMPLETED
-
Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil
NCT00853788 ·Status: COMPLETED
-
Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis
NCT07142473 ·Status: RECRUITING
-
Defining the Skin and Blood Biomarkers of Ichthyosis
NCT03417856 ·Status: ENROLLING_BY_INVITATION
-
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
NCT00613171 ·Status: COMPLETED ·Phase: PHASE2
-
Familial Systemic Scleroderma
NCT07343115 ·Status: RECRUITING
-
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
NCT02322255 ·Status: COMPLETED
-
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
NCT02422407 ·Status: COMPLETED
-
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02471352 ·Status: RECRUITING
-
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
NCT01309997 ·Status: COMPLETED ·Phase: PHASE2
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
Elastography Ultrasound in Localized Scleroderma (Morphea) Study
NCT06847750 ·Status: ENROLLING_BY_INVITATION
-
Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides
NCT05526638 ·Status: UNKNOWN ·Phase: NA
-
Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.
NCT02926963 ·Status: TERMINATED ·Phase: NA